gemcitabine has been researched along with ovalbumin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, Z; Digiovanni, J; Kiguchi, K; Kumar, A; Lansakara-P, DS; Rodriguez, BL; Sandoval, MA; Sloat, BR | 1 |
| Fox, SA; Jackaman, C; Majewski, D; Nelson, DJ; Nowak, AK | 1 |
| Bauer, C; Bauernfeind, F; Conrad, C; Dauer, M; Duewell, P; Eigler, A; Endres, S; Kiefl, R; Schnurr, M; Sterzik, A | 1 |
3 other study(ies) available for gemcitabine and ovalbumin
| Article | Year |
|---|---|
EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Epidermal Growth Factor; ErbB Receptors; Gemcitabine; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Ovalbumin; Tumor Burden | 2012 |
Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; Deoxycytidine; Epitopes; Female; Gemcitabine; Histocompatibility Antigens Class I; Interferon-gamma; Interleukin-2; Mesothelioma; Mice; Mice, Inbred C57BL; Ovalbumin; T-Lymphocytes, Cytotoxic; Transfection | 2012 |
Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
Topics: Adenocarcinoma; Animals; Antibody Specificity; Antimetabolites, Antineoplastic; B-Lymphocytes; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Immunity, Cellular; Immunity, Humoral; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Mice, Transgenic; Ovalbumin; Pancreatic Neoplasms; Peptide Fragments; Tumor Escape | 2014 |